Thermo Fisher Scientific-Robust Analytical Instruments Segment Likely to Aid TMO's Q4 Earnings

Earnings Release and Estimates - Thermo Fisher Scientific Inc (TMO) is scheduled to release its Q4 2024 results on Jan 30 before market open [1] - The Zacks Consensus Estimate for Q4 revenues is $11.25 billion, indicating 3.3% YoY growth [3] - The consensus estimate for Q4 earnings is$ 5.92 per share, suggesting 4.4% YoY growth [3] - Earnings estimates have remained unchanged at $5.92 per share over the past 30 days [4] Segment Performance Expectations Analytical Instruments - Expected to generate strong Q4 sales driven by newly launched cutting-edge technologies [5] - Introduced Thermo Scientific Iliad (Scanning) Transmission Electron Microscope in Q4 [5] - R&D 100 Awards honored Thermo Scientific Orbitrap Astral Mass spectrometer in Q3 [6] - Model projects$ 2.19 billion in Q4 revenues, representing 7.5% YoY growth [6] Life-Science Solutions - Likely experienced sales decline due to runoff of pandemic-related revenues [7] - Launched Applied Biosystems MagMAX Sequential DNA/RNA kit and Invitrogen Vivofectamine Delivery Solutions in Q3 [8] - Bioproduction business likely grew due to strong adoption in pharma and biotech segment [9] - Model expects $2.65 billion in Q4 revenues, indicating 7.5% YoY improvement [10] Specialty Diagnostics - Expected to gain positive contributions from transplant diagnostics and immunodiagnostics businesses [11] - Received FDA approval for Ion Torrent Oncomine Dx Target Test as companion diagnostic in Q4 [11] - Partnered with National Cancer Institute on myeloMATCH precision medicine trial in Q3 [12] - Model projects$ 1.13 billion in Q4 revenues, suggesting 2% YoY growth [13] Laboratory Products and Services - Revenues expected to increase due to research and safety market channel [14] - Introduced Thermo Scientific iCAP MX Series ICP-MS in Q4 [14] - Opened first electron microscopy demo center (NanoPort) in Taiwan and expanded global laboratory services with new bioanalytical lab in Sweden during Q3 [15] - Model expects $5.72 billion in Q4 revenues, flat YoY [16] Quantitative Model Predictions - Thermo Fisher has an Earnings ESP of +0.65% [17] - The company currently carries a Zacks Rank 4 [17] Other Medical Stocks to Watch - Argenx (ARGX) has Earnings ESP of +44.82% and Zacks Rank 2, expected to release Q4 2024 results on March 6 [18] - Arcutis Biotherapeutics (ARQT) has Earnings ESP of +7.97% and Zacks Rank 2, expected to release Q4 2024 results on Feb 25 [19] - Axogen (AXGN) has Earnings ESP of +36.36% and Zacks Rank 2, likely to release Q4 2024 results on March 4 [20]